GlassScriptPhysician profile
Amar Patel
NPI 1871882449
$1,766.99
in general payments reported to CMS, 2019-2025
17 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2021: $69.05 · 2022: $66.07 · 2023: $349 · 2024: $469 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.31 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $459.56 | 2019-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $248.48 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $235.70 | 2022-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $127.75 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.03 | 2019 | |
| Genentech USA, INC. | $92.11 | 2021-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $86.27 | 2025 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $85.08 | 2019 | |
| Genentech, INC. | $82.26 | 2023 | Vabysmo |
| E.R. Squibb & Sons, L.L.C. | $69.80 | 2025 | Camzyos |
| Astellas Pharma US INC | $63.98 | 2023-2024 | Izervay |
| Bausch & Lomb Americas INC. | $32.82 | 2023 | Vyzulta |
| Eyepoint US, INC. | $24.93 | 2022 | |
| Sandoz INC. | $20.11 | 2024 | Cimerli |
| Allergan, INC. | $17.87 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $16.00 | 2025 | Tissueblue, Eva, Combined Machine |
| Kala Pharmaceuticals, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.